vs
Side-by-side financial comparison of IONIS PHARMACEUTICALS INC (IONS) and Riley Exploration Permian, Inc. (REPX). Click either name above to swap in a different company.
IONIS PHARMACEUTICALS INC is the larger business by last-quarter revenue ($203.3M vs $113.9M, roughly 1.8× Riley Exploration Permian, Inc.). Riley Exploration Permian, Inc. runs the higher net margin — -61.8% vs -112.8%, a 51.0% gap on every dollar of revenue. On growth, Riley Exploration Permian, Inc. posted the faster year-over-year revenue change (11.2% vs -10.3%). Riley Exploration Permian, Inc. produced more free cash flow last quarter ($24.6M vs $-159.0M). Over the past eight quarters, IONIS PHARMACEUTICALS INC's revenue compounded faster (30.4% CAGR vs 3.9%).
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.
Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.
IONS vs REPX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $203.3M | $113.9M |
| Net Profit | $-229.4M | $-70.4M |
| Gross Margin | 96.1% | — |
| Operating Margin | -105.5% | 38.3% |
| Net Margin | -112.8% | -61.8% |
| Revenue YoY | -10.3% | 11.2% |
| Net Profit YoY | -119.8% | — |
| EPS (diluted) | $-1.35 | $-3.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.9M | ||
| Q4 25 | $203.3M | $97.3M | ||
| Q3 25 | $156.7M | $106.9M | ||
| Q2 25 | $452.0M | $85.4M | ||
| Q1 25 | $131.6M | $102.5M | ||
| Q4 24 | $226.6M | $102.7M | ||
| Q3 24 | $133.8M | $102.3M | ||
| Q2 24 | $225.3M | $105.4M |
| Q1 26 | — | $-70.4M | ||
| Q4 25 | $-229.4M | — | ||
| Q3 25 | $-128.6M | $16.3M | ||
| Q2 25 | $123.6M | $30.5M | ||
| Q1 25 | $-146.9M | $28.6M | ||
| Q4 24 | $-104.3M | — | ||
| Q3 24 | $-140.5M | $25.7M | ||
| Q2 24 | $-66.3M | $33.5M |
| Q1 26 | — | — | ||
| Q4 25 | 96.1% | — | ||
| Q3 25 | 98.5% | — | ||
| Q2 25 | 99.1% | — | ||
| Q1 25 | 98.9% | — | ||
| Q4 24 | 98.3% | — | ||
| Q3 24 | 99.2% | — | ||
| Q2 24 | 98.2% | — |
| Q1 26 | — | 38.3% | ||
| Q4 25 | -105.5% | 26.9% | ||
| Q3 25 | -102.2% | 27.0% | ||
| Q2 25 | 30.9% | 33.7% | ||
| Q1 25 | -111.6% | 48.3% | ||
| Q4 24 | -48.9% | 31.2% | ||
| Q3 24 | -111.1% | 17.1% | ||
| Q2 24 | -29.3% | 50.9% |
| Q1 26 | — | -61.8% | ||
| Q4 25 | -112.8% | — | ||
| Q3 25 | -82.1% | 15.3% | ||
| Q2 25 | 27.3% | 35.7% | ||
| Q1 25 | -111.6% | 27.9% | ||
| Q4 24 | -46.1% | — | ||
| Q3 24 | -105.0% | 25.1% | ||
| Q2 24 | -29.4% | 31.8% |
| Q1 26 | — | $-3.38 | ||
| Q4 25 | $-1.35 | $4.02 | ||
| Q3 25 | $-0.80 | $0.77 | ||
| Q2 25 | $0.70 | $1.44 | ||
| Q1 25 | $-0.93 | $1.36 | ||
| Q4 24 | $-0.66 | $0.52 | ||
| Q3 24 | $-0.95 | $1.21 | ||
| Q2 24 | $-0.45 | $1.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.7B | — |
| Total DebtLower is stronger | $1.8B | $240.7M |
| Stockholders' EquityBook value | $489.1M | $553.4M |
| Total Assets | $3.5B | $1.2B |
| Debt / EquityLower = less leverage | 3.71× | 0.43× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.1B | — |
| Q1 26 | — | $240.7M | ||
| Q4 25 | $1.8B | $247.9M | ||
| Q3 25 | — | $367.0M | ||
| Q2 25 | — | $275.2M | ||
| Q1 25 | — | $249.3M | ||
| Q4 24 | $1.3B | $269.5M | ||
| Q3 24 | — | $288.6M | ||
| Q2 24 | — | $322.7M |
| Q1 26 | — | $553.4M | ||
| Q4 25 | $489.1M | $634.2M | ||
| Q3 25 | $618.0M | $566.5M | ||
| Q2 25 | $631.7M | $556.9M | ||
| Q1 25 | $475.7M | $532.4M | ||
| Q4 24 | $588.4M | $510.6M | ||
| Q3 24 | $662.5M | $507.4M | ||
| Q2 24 | $263.7M | $489.0M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $3.5B | $1.2B | ||
| Q3 25 | $3.0B | $1.2B | ||
| Q2 25 | $3.0B | $1.0B | ||
| Q1 25 | $2.8B | $994.9M | ||
| Q4 24 | $3.0B | $993.5M | ||
| Q3 24 | $3.1B | $997.9M | ||
| Q2 24 | $2.7B | $1.0B |
| Q1 26 | — | 0.43× | ||
| Q4 25 | 3.71× | 0.39× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | 2.13× | 0.53× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.66× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-137.7M | $47.2M |
| Free Cash FlowOCF − Capex | $-159.0M | $24.6M |
| FCF MarginFCF / Revenue | -78.2% | 21.6% |
| Capex IntensityCapex / Revenue | 10.5% | 41.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-320.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $47.2M | ||
| Q4 25 | $-137.7M | $64.9M | ||
| Q3 25 | $-131.4M | $63.6M | ||
| Q2 25 | $151.3M | $33.6M | ||
| Q1 25 | $-150.8M | $50.4M | ||
| Q4 24 | $-116.1M | $66.4M | ||
| Q3 24 | $-115.0M | $72.1M | ||
| Q2 24 | $-119.9M | $51.6M |
| Q1 26 | — | $24.6M | ||
| Q4 25 | $-159.0M | — | ||
| Q3 25 | $-136.7M | — | ||
| Q2 25 | $139.0M | — | ||
| Q1 25 | $-163.4M | — | ||
| Q4 24 | $-141.6M | — | ||
| Q3 24 | $-124.0M | — | ||
| Q2 24 | $-126.1M | — |
| Q1 26 | — | 21.6% | ||
| Q4 25 | -78.2% | — | ||
| Q3 25 | -87.2% | — | ||
| Q2 25 | 30.8% | — | ||
| Q1 25 | -124.1% | — | ||
| Q4 24 | -62.5% | — | ||
| Q3 24 | -92.7% | — | ||
| Q2 24 | -56.0% | — |
| Q1 26 | — | 41.3% | ||
| Q4 25 | 10.5% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 11.3% | — | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 2.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.90× | ||
| Q2 25 | 1.22× | 1.10× | ||
| Q1 25 | — | 1.76× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.81× | ||
| Q2 24 | — | 1.54× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
REPX
Segment breakdown not available.
